Statistical analysis of the results obtained from therapeutic studies: study A
Percentage increase in lifespan, calculated as: [(median survival time in treated animals/median survival time in controls) − 1] × 100. Log-rank tests were used for statistical comparison between all the groups.
Group | Treatment | MDD (Range) | Change in Lifespan | Survivors Group | P Value (Control) | P Value (TPT4) | P Value (TPT5) | P Value (TPT6) | P Value (TPT7) |
|---|---|---|---|---|---|---|---|---|---|
| % | |||||||||
| TPT1 | Control; no treatment | 23 (12-31) | 0/10 | 1 | |||||
| TPT2 | Control; intravenous saline | 18 (12-31) | 0/10 | ||||||
| TPT3 | Control; intraperitoneal saline | 23 (6-35) | 0/10 | ||||||
| TPT4 | Topotecan; intravenously q7d × 3 | 28 (16-40) | 22 | 0/10 | 0.088 | 1 | |||
| TPT5 | Topotecan; intraperitoneally q7d × 3 | 31 (12-45) | 35 | 0/10 | 0.015 | 0.25 | 1 | ||
| TPT6 | Anti-VEGF; intraperitoneally 2×/week × 3 | 31 (20-45) | 35 | 0/10 | 0.0029 | 0.125 | 0.841 | 1 | |
| TPT7 | Anti-VEGF; intraperitoneally 2×/week × 3 + topotecan; intravenously q7d × 3 | 37 (35-50) | 61 | 0/10 | <0.001 | 0.0065 | 0.145 | 0.141 | 1 |
| TPT8 | Anti-VEGF; intraperitoneally 2×/week × 3 + topotecan; intraperitoneally q7d × 3 | 50 (40−60+) | 117 | 4/11 | <0.001 | <0.001 | <0.001 | <0.001 | 0.0015 |
MDD, median day of death.